TFI International remains a strong buy with solid cash flow, strategic growth, and new buying opportunities amid a recovering ...

CAVA's expansion boosts revenue, but slowing sales and high valuation raise concerns. Read here for an analysis of CAVA stock ...

Northwest Pipe's growth is set to surge in FY25, with improving margins, strong order momentum, and favorable stock valuation ...

Omada Health shows strong growth and innovation in chronic care but remains unprofitable with valuation, churn. See why OMDA ...

The median risk of default for publicly traded US companies rose across most sectors from the end of March through the end of ...

Generate consistent income with Sixth Street Specialty (TSLX) stock's 8.9% yield and strong distribution coverage. Read here ...

Torrid Holdings faces revenue challenges, e-commerce risks, and industry pressures. See here to know why we recommend a sell ...

More banks are racking up frequent losses, while the cumulative net loss at credit unions has jumped in recent periods.

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

Demand for private credit continues to surge, with projections suggesting it could hit $2.8 trillion by 2028. Read more here.

X Financial offers asymmetric upside with strong growth, stable asset quality, and a high ROE at a low valuation. Learn why ...

Aker ASA remains discounted to NAV, with steps like the Solstad IPO and Cognite's U.S. shift supporting value. See why AKAAF ...